Aim of the work: evaluatethe response rate , acute and late adverse effects of induction chemotherapy followed by concurrent chemoradiotherapy . secondary end points include overall survival and progression free survival in patients with locoregionally advanced of Squamous cell head and neck cancer (HNSCC) . Patients and Method: A retrospective study of 48 patientswith pathologically proven Stage III-IVB ofSquamous cell head and neck cancer (HNSCC) who presented to the clinical oncology department, sohag University hospital fromJanuary 2010 to March 2017. Patients were treated with induction chemotherapy followed by concurrent chemoradiation therapy or initially concurrentchemoradiation therapy. This study was conducted by hand search in the files and radiotherapy sheetof these patients. Results: Fourty_eight patients with locally advanced head and neck squamous cell carcinoma were included in this study. It was conducted at the Clinical Oncology and Nuclear Medicine Department, Sohag Faculty of Medicine .Of the 48 identified patients, 20 patients received IC followed with CCRT and 28 patients received only CCRT. Therewas no statistically significant difference between both groups as regards response at 24 , 36 and 45 months.In group of CCRT , 18 patients had CR to primary treatment , 7 Patients had PR and 7 Patients had Progressive disease . Ingroup of IC, 12 patients had CR ,6 patients had PR and one patient have Progressive disease . Acute skin reactions andacute mucositiswere experienced by all patients .There was no statistically significant difference between the two groups as regards xerostomia and Chronic skin and subcutaneous toxicity . Conclusion:Our findings did not show that adding induction chemotherapy to chemoradiotherapy was better than concurrent chemoradiotherapy alone in locally advanced head and neck cancer , so the latter remains standard therapy in patients with LAHNC .
Introduction
The annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year. (Jemal A et al 2011) About 90% of all head and neck cancers are squamous cell carcinomas (HNSCC). HNSCC is the sixth leading cancer by incidence worldwide. Pathological diagnosis should be made according to the World Health Organization classification from a surgical biopsy Sample . Routine staging includes physical examination, chest X-ray ,head and neck endoscopy, and head and neck computed tomography (CT) scan or magnetic resonance imaging (MRI) . Squamous cell head and neck cancer should be staged according to the TNM system. A multidisciplinary treatment schedule should be established in all cases. Treatment depends on primary tumor location and extension. In early stage (I-II), either conservative surgery or radiotherapy (external radiotherapy or brachytherapy) gives similar locoregional control. 
The Aim Of Work:
The main objective of this study is to determine the response rate , acute and late adverse effects of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy . secondary end points include over all survival and progression free survival in patients with locoregionally advanced of Squamous cell head and neck cancer (HNSCC) .
.Materials and Methods: From a retrospective database of 200 patients with HNSCC, we identified 48 patients with Stage III-IVB who were treated with induction chemotherapy followed by concurrent chemoradiation therapy or initially concurrent chemoradiation therapy. We included all available records of patients treated and received their routine follow-up at, Clinical Oncology and Nuclear Medicine Department, Sohag Faculty of Medicine ,during the period from January 2010 to March 2017 .
Ethical consideration:
The study was reviewed and accepted by the University Ethics Committee before enrollment .
Patients eligibility
Patients with pathologically proven non-metastatic, previously untreated, locally advanced HNSCC ,stage III or IV, were eligible. Patients were between 18 and 70 years of age, had a WHO performance status of 0&1. Exclusion criteria were Presence of any other comorbid disease . Evaluation during and posttreatment All patients were clinically evaluated twice a week during Treatment .Toxicity was evaluated weekly according to the RTOG Toxicity Criteria.
After completion of simultaneous treatment, 4 to 8 weeks were allowed for mucosal recovery before response assessment .Patients underwent routine follow-up starting one month after radiotherapy and followed every 2 months for 2 years, every 4 -6 months during years 3 -5 and yearly there after. Induction Chemotherapy ; Induction chemotherapy consisted of either TPF docetaxel (75 mg/m2) on day 1, cisplatin(75 mg/m2) on day 1, and 5-fluorouracil (750 mg/m2/d) on days1-5 for 2-3 cycles every 21 daysor PF ICT which consisted of cisplatin(80 mg/m2 ) on day 1 and 5-FU (1000 mg/m2)on days 1-5 as a continuous peripheral infusion,everythree weeks. 
Concurrent Chemotherapy

Results
Fourty_eight patients with locally advanced head and neck squamous cell carcinoma were included in this study , patients were treated with induction chemotherapy followed by concurrent chemoradiation therapy or initially concurrent chemoradiation therapy. It was conducted at the Clinical Oncology and Nuclear Medicine Department, Sohag Faculty of Medicine .
Patient Population and characteristics data Analysis
Of the 48 identified patients, 20 patients received IC followed with CCRT and 28 patients received only CCRT. The median age was 60 years ( range 18 -77 ) and 33 ( 68.75%) were male. Smoking history was positive in 29 (60.42% ) of the patients and 19 (39.58 %) never smoked. All patients included had an Eastern Cooperative Oncology Group PS 1 or less.
Analysis of Disease characteristics
Characteristic of the tumors in studied populations are listed in (Table 1 & 2 ) . The most common presentation was Hoarseness of voice 23 patients (47.92%) , followed by Dysphagia 8patients (16.67%) , Nasal obstruction 6 patients (12.50%) ,Neck mass 5 patients (10.42%) and less common Dyspnea ,Epistaxis , Facial swelling ,Lt. Facial pain , Rt. check mass and Stomatitis . The location of the primary disease was the larynx 26 patients (54.17%) , followed by the Nasopharynx 9 patients (18.75%) ,Hypopharynx 5 patients (10.42%)and Oral cavity andTongue each of them 3 patients (6.25%) . (68.75%) of the pathology were Undifferentiated Carcinoma followed by SCC (31.25%) . There is no statistically significant difference between the two groups as regards acute dysphagia which was equal in both groups ( 75.00 % of patients ) .
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Chronic toxicities: Xerostomia; There was no statistically significant difference between the two groups as regards xerostomia which experienced in (10.71%), (15.00%) of CCRT and IC respectively . Chronic skin and subcutaneous toxicity:although Chronic skin and subcutaneous toxicity were experienced in patients of CCRT group only (25.00% of patients ), no statistically significant difference between the two groups as regard chronic skin and subcutaneous toxicity. We found inOur study that the tested regimen showed a nearly equal tumor response rate and survival results in comparison with the control regimen.
Comparison between patients using / not using induction chemotherapy according to toxicity These reports solidified concomitant chemoradiotherapy as a treatment standard in the definitive management of locoregionally advanced HNSCC. Induction chemotherapy remained investigational except in the larynx preservation setting . In our study we observed no statistically significant of acute and late toxicities of both arm , Acute mucositis was experienced by all patients of both arm, The high grades of acute mucositis (grade 3 and 4) were frequently experienced in patients of CCRT group (39.28 ofpatients) and IC group (40.00% of patients ) which in general less than in CONDOR study (C.M.L. Driessen ,2016) .
There is no statistically significant difference between the two groups as regards acute dysphagia and Xerostomia Retrospective studies are less solid for these types of conclusions, especially in patients with SCCHN. This is due to the presence of heterogeneous type of tumors sites, stages, patient populations (resectable and an unresectable populations), schedule of chemotherapy and radical treatments(radiotherapy, surgery/ radiotherapy and chemoradiotherapy) . For all these reasons, the real benefit of ICT is still controversial, so A costbenefit and quality-of-life analysis might prove beneficial in addressing the true value of induction chemotherapy. Finally , The question of whether the addition of induction chemotherapy to concurrent chemoradiotherapy improved survival over concurrent chemoradiotherapy alone remains unfortunately unanswered and it might not be answered soon . Conclusions ; Our findings did not show that adding induction chemotherapy to chemoradiotherapy was better than concurrent chemoradiotherapy alone in locally advanced head and neck cancer , so the latter remains standard therapy in patients with LAHNC .
